ANAlessandro Nava

Alessandro Nava

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Nava has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exercise Prescription in Cardio-Oncology

    by Nicola Campana, Luca Fazzini, Clelia Donisi, Alessandro Nava, Michele Migliari, Martino Deidda, Andrea Pretta, Mario Scartozzi, Christian Cadeddu Dessalvi

    Numerous studies underscore the benefits of exercise prescription in both cardiology and oncology. Recently, emerging eviAlessandro Navadence has highlighted the value of exercise in cardio-oncology, demonstrating its protective effects against the decline in functional capacity and cardiovascular complications that may arise in oncology patients, either as a result of the disease itself or as a side effect of chemotherapy. The purpose of this review is to elucidate the protective mechanisms and cardiovascular clinical benefits conferred by exercise prescription in cancer patients. Additionally, it aims to delineate the principal current exercise protocols that have been validated or proposed, outlining their respective advantages and limitations. Finally, we will explore future perspectives, particularly the development of precision medicine, supported by advancements in AI, to facilitate the creation of novel, personalized exercise protocols tailored to specific patient populations.


  • Open Access

    Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban

    by Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, Nicolò Capra, Alice Bonomi, Gaia Cattadori, Beatrice Pezzuto, Jeness Campodonico, Arianna Piotti, Alessandro Nava, et al.

    Introduction: Risk stratification in heart failure (HF) is essential for clinical and therapeutic management. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score is a validated prognostic model for assessing cardiovascular risk in HF patients with reduced ejection fraction (HFrEF). From the validation of the score, the prevalence of HF patients treated with direct oral anticoagulants (DOACs), such as edoxaban, for non-valvular atrial fibrillation (NVAF) has been increasing in recent years. This study aims to evaluate the reliability of the MECKI score in HFrEF patients treated with edoxaban for NVAF. Materials and Methods: This study included consecutive outpatients with HF and NVAF treated with edoxaban (n = 83) who underwent a cardiopulmonary exercise test (CPET). They were matched by propensity score with a retrospective group of HFrEF patients with NVAF treated with vitamin K antagonists (VKAs) from the MECKI score registry (n = 844). The study endpoint was the risk of cardiovascular mortality, urgent heart transplantation, or Left Ventricle Assist Device (LVAD) implantation. Results: Edoxaban patients were treated with a more optimized HF therapy and had different clinical characteristics, with a similar MECKI score. After propensity score, 77 patients treated with edoxaban were successfully matched with the MECKI-VKA control cohort. In both groups, MECKI accurately predicted the composite endpoint with similar area under the curves (AUC = 0.757 vs. 0.829 in the MECKI-VKA vs. edoxaban-treated group, respectively, p = 0.452). The two populations’ survival appeared non-significantly different at the 2-year follow-up. Conclusions: this study confirms the prognostic accuracy of the MECKI score in HFrEF patients with NVAF treated with edoxaban, showing improved predictive power compared to VKA-treated patients.